Participant Basic Agreement (PBA) Opportunity - Threat Agnostic Host-Directed Therapeutics
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Department of the Army's Capability Program Executive for Chemical, Biological, Radiological, and Nuclear Defense (CPE CBRND) invites participation in the HEALER portfolio, a continuous opportunity to develop threat-agnostic, host-directed therapeutics. This initiative seeks to enhance the body's resilience against CBRN threats, focusing on dual-use solutions with commercial market potential. The program will be executed under a Participant Basic Agreement (PBA).
Program Vision & Scope
The HEALER portfolio aims to create a new generation of therapeutics that enable the host to recover from physiological impacts and maintain operational effectiveness. The program targets medical countermeasures providing layered physiological protection by focusing on critical host systems, including:
- Neurological Protection
- Respiratory Stabilization
- Immune Modulation
- Hematologic & Vascular Function
- Cellular Stress & Repair Pathways
Call for Collaborators
This announcement is open to the full spectrum of drug development organizations:
- Therapeutic Development Collaborators: Developers of host-directed therapeutic candidates.
- Drug Development Support Collaborators: Organizations specializing in contract research, development, and manufacturing (CROs/CDMOs), preclinical testing (efficacy, pharmacology, toxicology), clinical trial execution, cGMP manufacturing, regulatory submissions, and advanced modeling.
Submission Requirements
Interested entities must submit a white paper (not to exceed five pages, excluding cover page). Submissions should also state the entity's willingness to team or collaborate with other PBA holders for the HEALER portfolio.
For Therapeutic Development Collaborators, the white paper should cover:
- Product Description (mechanism of action, pathways, intended use, FDA indication)
- Efficacy Data (in vivo/in vitro, validated animal models against CBRN threats)
- Regulatory & Clinical Status (FDA experience, IND status, clinical trials, safety/PK/PD data)
- Manufacturing (capacity, GMP status, scaling strategy)
- Company Profile (experience, commercialization, IP rights)
For Drug Development Support Collaborators, the white paper should summarize:
- Core capabilities
- Relevant experience (complex biologics/small molecules, FDA regulatory)
- Available infrastructure and technology to accelerate development.
Contract Details & Administrative Information
- Agreement Type: Participant Basic Agreement (PBA).
- Authority: 10 U.S.C. §§ 4021, 4022, and 4023 (not subject to CICA).
- Set-Aside: None specified.
- Response Date: This is a continuous, open announcement with no specific deadline unless noted.
- SAM Registration: Prospective awardees must be registered in SAM prior to invoicing and through final payment.
Points of Contact
- Hunter Robinson (hunter.t.robinson4.civ@army.mil)
- Alexander Mayatte (alexander.z.mayatte.civ@army.mil)